Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Hold Rolls-Royce Holdings (RR.) by Christopher Ruane in The Motley Fool
- Buy Sainsbury (J) (SBRY) by Christopher Ruane in The Motley Fool
- Buy Vodafone Group (VOD) by Christopher Ruane in The Motley Fool
- Buy British American Tobacco (BATS) by Christopher Ruane in The Motley Fool
- Buy Legal & General Group (LGEN) by Christopher Ruane in The Motley Fool
- Buy Income & Growth VCT (IGV) by Christopher Ruane in The Motley Fool
- Neutral Aviva (AV.) by Goldman Sachs
- Hold International Consolidated Airlines Group SA (CDI) (IAG) by Kepler Cheuvreux
- Buy Advanced Medical Solutions Group (AMS) by Liberum Capital
- Neutral Balfour Beatty (BBY) by UBS
- Neutral Aston Martin Lagonda Global Holdings (AML) by ODDO BHF
- Long Term Buy Schroders (SDR) by John Maslen in The Motley Fool
- Neutral British American Tobacco (BATS) by Goldman Sachs
- Underweight GSK (GSK) by JP Morgan
- Buy NCC Group (NCC) by Jefferies
- Buy Foxtons Group (FOXT) by Jon Smith in The Motley Fool
- Buy Greencoat UK Wind (UKW) by Jon Smith in The Motley Fool
- Buy Luceco (LUCE) by Harshil Patel in The Motley Fool
- Buy Up Global Sourcing Holdings (UPGS) by Harshil Patel in The Motley Fool
- Long Term Buy Rio Tinto (RIO) by Harshil Patel in The Motley Fool
Immupharma (IMM)
Health Care Sector
Members only
To view this content and much more please Sign Up
NOTE: This is based on 7 open tips for this company
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Immupharma Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.Latest Immupharma Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | Northland Capital | – | 2018-04-17 16:35:00 17/04/2018 | – |
| – | Paul Summers | – | 2018-03-01 09:50:00 01/03/2018 | – |
| – | FinnCap | – | 2017-12-21 11:30:00 21/12/2017 | – |
| – | FinnCap | – | 2017-12-12 08:00:00 12/12/2017 | – |
| – | Harvey Jones | – | 2017-10-09 15:30:00 09/10/2017 | – |
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Immupharma Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.Latest Immupharma Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | Northland Capital | – | 2018-04-17 16:35:00 17/04/2018 | – |
| – | Paul Summers | – | 2018-03-01 09:50:00 01/03/2018 | – |
| – | FinnCap | – | 2017-12-21 11:30:00 21/12/2017 | – |
| – | FinnCap | – | 2017-12-12 08:00:00 12/12/2017 | – |
| – | Harvey Jones | – | 2017-10-09 15:30:00 09/10/2017 | – |